Literature DB >> 24002558

Kidney disease in pregnancy: (Women's Health Series).

Geeta Gyamlani1, Stephen A Geraci.   

Abstract

Kidney disease and pregnancy may exist in two general settings: acute kidney injury that develops during pregnancy, and chronic kidney disease that predates conception. In the first trimester of pregnancy, acute kidney injury is most often the result of hyperemesis gravidarum, ectopic pregnancy, or miscarriage. In the second and third trimesters, the common causes of acute kidney injury are severe preeclampsia, hemolysis-elevated liver enzymes-low platelets syndrome, acute fatty liver of pregnancy, and thrombotic microangiopathies, which may pose diagnostic challenges to the clinician. Cortical necrosis and obstructive uropathy are other conditions that may lead to acute kidney injury in these trimesters. Early recognition of these disorders is essential to timely treatment that can improve both maternal and fetal outcomes. In women with preexisting kidney disease, pregnancy-related outcomes depend upon the degree of renal impairment, the amount of proteinuria, and the severity of hypertension. Neonatal and maternal outcomes in pregnancies among renal transplant patients are generally good if the mother has normal baseline allograft function. Common renally active drugs and immunosuppressant medications must be prescribed, with special considerations in pregnant patients.

Entities:  

Mesh:

Year:  2013        PMID: 24002558     DOI: 10.1097/SMJ.0b013e3182a5f137

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Kidneys and women's health: key challenges and considerations.

Authors:  Gloria E Ashuntantang; Vesna D Garovic; Ita P Heilberg; Liz Lightstone
Journal:  Nat Rev Nephrol       Date:  2018-01-30       Impact factor: 28.314

Review 2.  Hypertensive disorders in pregnancy.

Authors:  Casey Berry; Mohamed G Atta
Journal:  World J Nephrol       Date:  2016-09-06

Review 3.  Obstetric and offspring risks of women's morbid conditions linked to prior anticancer treatments.

Authors:  Juan J Tarín; Miguel A García-Pérez; Antonio Cano
Journal:  Reprod Biol Endocrinol       Date:  2016-07-07       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.